Patients ask me two opposite questions in the same week: “Doctor, am I sick enough to need a transplant?” and “Doctor, am I too sick for one?” Both are the right question, because a liver transplant is a timing decision, not a last resort or a default treatment for every damaged liver. In my practice, I evaluate a patient when living with the diseased liver has become more dangerous than the surgery itself — that single principle drives every test, score, and conversation below.

One correction I make early with almost every patient: most of what you’ll read online about transplant eligibility is written for the American deceased-donor system. In India, roughly 8 in 10 liver transplants are living donor (LDLT) — a family member gives part of their liver. That changes the eligibility conversation substantially. It isn’t “how sick do you have to be to move up a waiting list” — it’s “is transplant the right call, and do you have a donor.” I’ll flag where this distinction matters throughout.

Does Everyone With Cirrhosis Need a Transplant? No.

Cirrhosis has two clinically distinct phases, and only one puts transplant on the table.

Compensated cirrhosis — the liver is scarred but still functioning. Patients are often working, asymptomatic, with no fluid buildup or confusion. This group needs monitoring, not transplant evaluation.

Decompensated cirrhosis — the liver has stopped keeping up. This is the group I actually start evaluating:

Recurrent ascites (fluid buildup)
Spontaneous bacterial peritonitis
Jaundice
Hepatic encephalopathy (confusion)
Variceal bleeding
Worsening kidney function
Sarcopenia (muscle wasting)
Repeated hospital admissions for any of the above

Case — early referral changed the outcome. A 55-year-old male presented with acute-on-chronic liver failure, deteriorating rapidly — the kind of presentation where the decision window can be as tight as 2 to 3 days. His wife came forward as donor; she wasn’t a blood-group match, so the transplant proceeded as ABO-incompatible, within a selected-cohort protocol where survival outcomes run 80–85% in appropriately selected, desensitized cases. Early recognition and early transplant, not last-minute rescue, was what made survival possible.

What Actually Causes the Liver Disease That Leads Here

MASLD (formerly NAFLD/fatty liver) — the fastest-growing indication in India right now
Alcohol-related liver disease
Chronic hepatitis B and C
Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis
Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency
Acute liver failure (days-long deterioration in a previously healthy liver — this one moves fast)
Selected hepatocellular carcinoma (HCC)

How I Actually Decide — Beyond the Lab Numbers

This is the part that separates a real evaluation from a checklist.

Disease severity numbers matter — bilirubin, INR, creatinine, sodium, albumin, platelets, imaging. But how MELD gets used changes entirely depending on whether we’re considering DDLT or LDLT, and this is where most patient-facing content gets it backwards.

	DDLT (Deceased Donor)	LDLT (Living Donor)
Role of MELD score	Drives allocation — “sickest first” on a waitlist	Measures surgical risk, not queue position
Ideal patient state	Higher MELD moves you up the list	Moderate/lower MELD often tolerates surgery better
Waiting	Determined by organ availability	Planned around donor readiness
Risk of waiting too long	Patient may not survive to allocation	Patient may become too sick to safely undergo LDLT
India relevance	~20% of transplants	~80% of transplants

Wait too long for MELD to climb, and an LDLT candidate can become too sick to safely survive the surgery — the opposite of how DDLT logic works. This is exactly why early evaluation, long before a patient is critically ill, matters more in India’s LDLT-majority reality than it does in a pure allocation-queue system.

On cancer eligibility specifically: I don’t work off a rigid checklist like Milan criteria alone. Tumor size and number are a starting point, not the whole picture — vascular invasion, response to bridging therapy, and overall liver reserve all factor into whether transplant is the right call for a given patient.

Physical fitness for major surgery — heart, lung, kidney function, nutritional status, frailty, infection status all get assessed.

Psychological and family readiness — lifelong medication adherence isn’t optional after transplant, and I look for whether a patient and their support system understand that before, not after, listing.

Case — delayed referral, severe alcoholic hepatitis. One of the most heartbreaking patterns I see: patients with severe alcoholic hepatitis reaching a tertiary center only after multi-organ failure has already set in. By the time they arrive in the ICU, the critical window for intervention has closed — infection often rules out standard therapy, and an unstable patient can’t safely undergo transplant evaluation. This pattern disproportionately hits patients in their 30s and 40s with young families. Severe alcoholic hepatitis is a medical emergency, not a wait-and-watch diagnosis — early referral to a specialized liver unit is the decisive factor between a second chance and a preventable outcome.

When You Do NOT Need a Transplant

Compensated, stable cirrhosis
Reversible liver injury
Early fibrosis
Successfully treated hepatitis
MASLD without decompensation

Case — recovered without transplant. A young male came in with a first episode of severe alcoholic hepatitis — Maddrey discriminant function above 80, a picture that looked transplant-bound. A sepsis screen was negative. With steroid therapy and aggressive nutritional support, he recovered fully without transplantation. Evaluation isn’t a pipeline toward surgery. Sometimes the right call is intensive medical management, and a first-episode presentation with good support behind it is exactly where that call gets made.

When Transplant Isn’t Possible Yet (Not Never)

Active uncontrolled infection
Ongoing alcohol or substance use
Severe uncontrolled cardiac disease
Malignancy outside transplant criteria
Not currently fit for major surgery

Most of these are reversible with treatment first — this is a “not now,” not a permanent door closing, and I make a point of telling patients that distinction explicitly.

Living Donor vs. Deceased Donor — The Part Most Articles Underweight

In India, this is usually the real fork in the road, not MELD-based queue position.

LDLT (living donor):

Shorter wait, planned timing
Avoids deterioration while waiting
Requires a compatible, willing, medically fit donor — usually family
Donor evaluation is its own rigorous process (blood group compatibility, graft-to-recipient weight ratio, psychological and social assessment to rule out coercion)

DDLT (deceased donor):

No risk to a living donor
Dependent on organ availability through state allocation (ZTCC in Maharashtra) — realistically longer and less predictable than in countries with larger deceased-donor pools

Family counseling for LDLT is one of the most delicate parts of this practice — we’re no longer just treating a patient, we’re asking a perfectly healthy person to undergo major surgery. My responsibility in these sessions is absolute transparency: confirming the donor is stepping forward voluntarily, free of unspoken family pressure or guilt, and laying out the unvarnished risks, the dual recovery timeline, and the emotional, physical, and financial toll on the whole household. A successful LDLT needs a unified, realistic, committed family — not just surgical precision. Nobody leaves that conversation without understanding that the donor’s wellbeing is the one non-negotiable in the room.

Case — where a strict checklist would have said no. A patient presented with HCC beyond Milan criteria but within UCSF criteria — tumor burden that a rigid Milan-only cutoff would have excluded from transplant altogether. Based on overall liver reserve, response to bridging therapy, and absence of vascular invasion, we proceeded to transplant rather than turning the patient away on the strength of one number. This is exactly why I treat Milan as a starting reference, not a hard boundary — UCSF and other extended criteria exist precisely because tumor biology doesn’t always respect the tightest cutoff.

Myths I Correct Weekly

“I’m too old.” Physiological fitness matters more than age on paper.
“My last blood test looked fine, so I’m off the hook.” Isolated lab values matter less than complications and trajectory.
“Cancer rules out transplant.” Not automatically — see above.
“Transplant is my last resort.” It’s a planned treatment when timed right, not a rescue attempted too late.

FAQ

Can my liver recover without a transplant?
Depending on the cause and severity, yes — this is exactly what evaluation is for. Many patients referred for evaluation end up on medical management instead.

How long does evaluation take?
It depends entirely on how sick the patient is at presentation. In an acute, rapidly deteriorating case — acute liver failure or ACLF — we can complete evaluation in 12 to 24 hours because the decision window is that tight. In a stable, elective LDLT work-up, the same evaluation typically takes 8 to 10 days to complete the full medical, surgical, and donor assessment properly.

Can I return to work after transplant?
Most patients do, once recovery and immunosuppression are stabilized. Timelines vary by individual health status and job type.

Will I need medication for life?
Yes — lifelong immunosuppression is non-negotiable to prevent rejection.

Don’t Wait Until You’re Critically Ill to Ask

Evaluation doesn’t commit you to surgery — it tells you where you actually stand, and in decompensating liver disease, time is the one resource you can’t get back once it’s gone. Treating the patient, not just the numbers, is what makes a transplant truly successful.

If you or a family member are dealing with advanced liver disease and want an honest assessment of where things stand, I see patients in person at Gleneagles Hospital, Mumbai, and offer international virtual consultations for families evaluating options from abroad. Reach out at dr.chetankalal@gmail.com to start that conversation.

— Dr. Chetan Kalal, Hepatologist & Liver Transplant Specialist